83732-75-6

Basic information

• Product Name: 2-(2-AMINOETHYL)-1-METHYLPYRROLIDINE
• Synonyms: 2-(1-METHYL-PYRROLIDIN-2-YL)-ETHYLAMINE;2-(2'-AMINOETHYL)-1-N-METHYLPYRROLIDINE;2-(2-AMINOETHYL)-N-METHYL PYRROLIDINE;1-METHYL-2-(2-AMINOETHYL) TETRAHYDROPYRROLE;1-methyl-1H-pyrrole-2-ethylamine;2-(2-AMINOETHYL)-1-METHYLPYRROLE;1-Methyl-1H-pyrrole-2-ethanamine;2-(1-Methyl-1H-pyrrol-2-yl)ethylamine
• CAS NO: 83732-75-6
• Molecular Formula: C₇H₁₂N₂
• Molecular Weight: 128.22
• EINECS: 280-626-0
• Mol File: 83732-75-6.mol
• Article Data: 9

Chemical Properties

• Boiling Point: 232.1 °C at 760 mmHg
• Flash Point: 149 °F
• Appearance: /
• Density: 0.885 g/mL at 25 °C(lit.)
• Vapor Pressure: 0.083mmHg at 25°C
• Refractive Index: n20/D 1.4684(lit.)
• PKA: 10.40±0.10(Predicted)
• CAS DataBase Reference: 2-(2-AMINOETHYL)-1-METHYLPYRROLIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(2-AMINOETHYL)-1-METHYLPYRROLIDINE(83732-75-6)
• EPA Substance Registry System: 2-(2-AMINOETHYL)-1-METHYLPYRROLIDINE(83732-75-6)

Safety Data

• Hazard Codes: Xn,Xi
• Statements: 22-37/38-41
• Safety Statements: 26-39
• WGK Germany: 2
• Hazardous Substances Data: 83732-75-6(Hazardous Substances Data)

Usage

General Description

2-(2-aminoethyl)-1-methylpyrrolidine is a chemical compound containing a pyrrolidine ring with a methyl and an aminoethyl group attached to it. It is commonly used in the synthesis of pharmaceuticals and other organic compounds. 2-(2-AMINOETHYL)-1-METHYLPYRROLIDINE has potential biological activity and can be used as a building block in drug discovery and development. It can also serve as a precursor in the production of various chemicals and materials. Additionally, 2-(2-aminoethyl)-1-methylpyrrolidine may have applications in research and development and in the manufacturing of various industrial products.

InChI:InChI=1/C7H12N2/c1-8-6-4-7-3-2-5-9-7/h2-3,5,8-9H,4,6H2,1H3

Upstream product

• 24437-41-0 1-methyl-2-pyrroleacetonitrile 
• 100446-35-3 1-methyl-2-(2-nitroethenyl)-1H-pyrrole 
• 100446-35-3 1-methyl-2-(E-2-nitroethenyl)-1H-pyrrole 
• 1192-58-1 N-methylpyrrole aldehyde 
• 54828-80-7 N,N,N,1-tetramethyl-1H-pyrrole-2-methanaminium iodide 

Downstream Products

• 157158-56-0 Carbonic acid benzyl ester 2,6-dimethoxy-4-((5R,5aR,8aR,9S)-9-{[2-(1-methyl-1H-pyrrol-2-yl)-ethylcarbamoyl]-methyl}-6-oxo-5,5a,6,8,8a,9-hexahydro-furo[3',4':6,7]naphtho[2,3-d][1,3]dioxol-5-yl)-phenyl ester 
• 369652-13-1 2-(2-hydroxy-ethyl)-N-[2-(1-methyl-1H-pyrrol-2-yl)-ethyl]-benzamide 
• 369652-07-3 3-(2-hydroxyethyl)-1H-indole-2-carboxylic acid [2-(1-methyl-1H-pyrrol-2-yl)-ethyl]-amide 
• 569351-25-3 1-methyl-6,7-dihydro-1H-pyrrolo[3,2-c]pyridine 
• 569351-26-4 1-methyl-4,5,6,7-tetrahydro-1H-pyrrolo[3,2-c]pyridine 
• 835612-36-7 4-[3-(4-{3-[2-(4-chloro-phenoxymethyl)-4-methyl-benzoimidazol-1-yl]-propyl}-piperidin-1-yl)-propyl]-1-methyl-1,4,6,7-tetrahydro-pyrrolo[3,2-c]pyridine-5-carboxylic acid tert-butyl ester 
• 102839-50-9 1,4-dimethyl-1H-pyrrolo<3,2-c>pyridine 

Relevant articles and documents

Novel fused pyrrole heterocyclic ring systems as structure analogs of LE 300: Synthesis and pharmacological evaluation as serotonin 5-HT2A, dopamine and histamine H1 receptor ligands

LE 300 represents a structurally novel type of antagonists acting preferentially at the dopamine D1/D5 receptors and the serotonin 5-HT2A receptor. This compound consists of a ten-membered central azecine ring fused to an indole ring on one side and a benzene moiety on the other side. To estimate the importance of the indole and / or phenyl moieties in this highly active benzindolo-azecine, both rings were removed and replaced with a 1H-pyrrole counterpart. Accordingly, some new analogs of LE 300 namely, pyrrolo[2,3-g]indolizine, pyrrolo[3,2-a]quinolizine rings and their corresponding dimethylpyrrolo[2,3-d]azonine, and dimethylpyrrolo[2,3-d]azecine were synthesized to be evaluated for their activity at the 5-HT2A and dopamine D1, D2L, D4, D5 receptors in relation to LE 300. In addition, their activity at the H1-histamine receptors was also determined. The results suggested that the rigid pyrrolo[2,3-g] indolizine 7 and pyrrolo[3,2-a]quinolizine 8 analogs lacked biological activity in the adopted three bioassays. However, their corresponding flexible pyrrolo[2,3-d]azonine 11 and pyrrolo[2,3-d]azecine 12 derivatives revealed weak partial agonistic activity and weak antagonistic potency at the serotonin 5-HT2A and histamine H1 receptors, respectively. Meanwhile, they showed no affinity to any of the four utilized dopamine receptors. Variation in ring size did not contribute to a significant influence on the three tested bioactivities. Removal of the hydrophobic moiety (phenyl ring) and replacement of the indole moiety with a 1H-pyrrole counterpart led to a dramatic alteration in the profile of activity of such azecine-type compounds.

CINNAMIC ACID AMIDE DERIVATIVE

The present invention provides a cinnamic acid amide derivative having an excellent analgesic action. The cinnamic acid amide derivative of the present invention is a compound showing excellent analgesic actions to not only a nociceptive pain model animal but also a neuropathic pain model animal, which is very useful as an agent for treating various pain diseases showing acute or chronic pains or neuropathic pains.

SUBSTITUTED QUINAZOLINE DERIVATIVES AND THEIR USE AS INHIBITORS

The use of a compound of formula (I) 1 or a salt, ester or amide thereof; where X is O, or S, S(O) or S(O)2, or NR6 where R6 is hydrogen or C1-6 alkyl,; R5 is an optionally substituted 5-membered heteroaromatic ring, R1, R2 ,R3, R4 are independently selected from various specified moieties, in the preparation of a medicament for use in the inhibition of aurora 2 kinase. Certain compounds are novel and these, together with pharmaceutical compositions containing them are also described and claimed